{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:37:35Z","timestamp":1793151455923,"version":"4.5.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UNICEF BANGKOK THAILAND"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There are gaps in knowledge and experience of antiretroviral pre-exposure prophylaxis (PrEP) delivery in adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This pilot study enrolled Thai adolescents 14\u201320 year-old without HIV who reported risk behaviour. All participants were offered daily tenofovir\/emtricitabine (TDF-FTC) and followed for 24 weeks. HIV testing, renal function, bone density scan, and sexually transmitted infection (STI) testing including syphilis serology and urine molecular testing for gonorrhoea and\n                      <jats:italic>C<\/jats:italic>\n                      .\n                      <jats:italic>trachomatis<\/jats:italic>\n                      were performed at baseline and weeks 12 and 24. Adherence was evaluated through intracellular tenofovir diphosphate (TFV-DP) levels in dried blood spots.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 61 enrolled adolescents, median age 18.1 (IQR: 14.8\u201320.9) years, 46 (75.4%) were males and 36 (59%) were MSM. Retention to week 24 was 80.3%. One third (36%) had TFV-DP levels consistent with taking \u22656 pills\/week at week 12 and 29% at week 24. The factors associated with taking \u22656 pills\/week were being MSM (adjusted odds ratio [aOR]: 53.2, 95% CI: 1.6\u20131811;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.027), presence of STI at baseline (aOR: 9.4, 95% CI: 1.5\u201358.5;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.016), and self-report of decreased condom use while taking PrEP (aOR: 8.7, 95% CI: 1.4\u201356.6;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.023). 31% had an STI at baseline and this declined to 18% at week 24. No renal or bone toxicity was observed and there were no HIV seroconversions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Daily oral PrEP with FTC-TDF in high-risk Thai adolescents is feasible, accepted, well-tolerated, and had no increased risk compensation; however, low adherence was a major challenge. Adolescent-specific PrEP strategies including long-acting modalities are needed for successful HIV prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0298914","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T13:29:56Z","timestamp":1708608596000},"page":"e0298914","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["A pilot program of HIV pre-exposure prophylaxis in Thai youth"],"prefix":"10.1371","volume":"19","author":[{"given":"Supattra","family":"Rungmaitree","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peerawong","family":"Werarak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadchara","family":"Pumpradit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanatpreeya","family":"Phongsamart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keswadee","family":"Lapphra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orasri","family":"Wittawatmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuitiang","family":"Durier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Maleesatharn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beena","family":"Kuttiparambil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-0974","authenticated-orcid":true,"given":"Tim R.","family":"Cressey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa M.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0140-4600","authenticated-orcid":true,"given":"Kulkanya","family":"Chokephaibulkit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"pone.0298914.ref001","unstructured":"World Health Organization. Estimated number of people (all ages) living with HIV 2021. Available from: https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/estimated-number-of-people-living-with-hiv."},{"key":"pone.0298914.ref002","unstructured":"World Health Organization. HIV. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"pone.0298914.ref003","unstructured":"UNICEF. Monitoring the situation of children and women. Available from: https:\/\/data.unicef.org\/topic\/hivaids\/adolescents-young-people\/."},{"key":"pone.0298914.ref004","unstructured":"UNAIDS. Putting young key populations first\u2013HIV and young people from key populations in the Asia and Pacific Region 2022; Accessed December 10, 2023. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2022-HIV-young-people-keypopulations-asia-pacific_en.pdf."},{"key":"pone.0298914.ref005","unstructured":"UNICEF. Situational analysis of young people at high risk of HIV exposure in Thailand. Available from: https:\/\/www.unicef.org\/thailand\/media\/1076\/file\/Situational%20Analysis%20of%20Young%20People%20at%20High%20Risk%20of%20HIV%20Exposure%20in%20Thailand.pdf."},{"key":"pone.0298914.ref006","first-page":"137","article-title":"Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives","volume":"8","author":"DM Machado","year":"2017","journal-title":"Adolesc Health Med Ther"},{"issue":"3","key":"pone.0298914.ref007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6903a1","article-title":"Preexposure prophylaxis for prevention of HIV acquisition among adolescents: clinical considerations, 2020","volume":"69","author":"MR Tanner","year":"2020","journal-title":"MMWR Recommendations and Reports"},{"issue":"3","key":"pone.0298914.ref008","doi-asserted-by":"crossref","first-page":"e25540","DOI":"10.1002\/jia2.25540","article-title":"Evaluation of a pre\u2010exposure prophylaxis programme for men who have sex with men and transgender women in Thailand: learning through the HIV prevention cascade lens","volume":"23","author":"RA Ramautarsing","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"pone.0298914.ref009","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MOP.0000000000000512","article-title":"HIV pre-exposure prophylaxis for adolescents and young adults","volume":"29","author":"EB Allen","year":"2017","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"pone.0298914.ref010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0298914.ref011","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"pone.0298914.ref012","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"JM Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"10013","key":"pone.0298914.ref013","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"S McCormack","year":"2016","journal-title":"Lancet"},{"issue":"27","key":"pone.0298914.ref014","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"pone.0298914.ref015","unstructured":"CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142017 update: a clinical practice guideline. Atlanta, GA: US Department of Health and Human Services, CDC; 2018. https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2017.pdf."},{"key":"pone.0298914.ref016","unstructured":"Gilead Sciences Inc. U.S. Food and Drug Administration approves expanded indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for reducing the risk of acquiring HIV-1 in adolescents [Press release]. Foster City, CA: Gilead Sciences Inc.; 2018."},{"key":"pone.0298914.ref017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12981-015-0053-z","article-title":"Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand","volume":"12","author":"Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group","year":"2015","journal-title":"AIDS Res Ther"},{"key":"pone.0298914.ref018","unstructured":"Thai Ministry of Public Health. Thailand National Guidelines for Pre-Exposure Prophylaxis (PrEP) 2021. Available from: https:\/\/www.prepthai.net\/Paper\/PrEP_Guidelines.pdf"},{"key":"pone.0298914.ref019","unstructured":"Bureau of AIDs TB and STIs. Report number of Thai PrEP users. Available from: https:\/\/www.prepthai.net\/ViewCascade.aspx."},{"issue":"1","key":"pone.0298914.ref020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0000000000001179","article-title":"An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM","volume":"74","author":"Adolescent Trials Network (ATN) for HIVAIDS Interventions","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"pone.0298914.ref021","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamapediatrics.2017.2007","article-title":"Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States","volume":"171","author":"SG Hosek","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"1","key":"pone.0298914.ref022","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/infdis\/jiw077","article-title":"A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine","volume":"214","author":"ML Cottrell","year":"2016","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0298914.ref023","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/aid.2012.0089","article-title":"Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure","volume":"29","author":"JR Castillo-Mancilla","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"5","key":"pone.0298914.ref024","doi-asserted-by":"crossref","first-page":"e97218","DOI":"10.1371\/journal.pone.0097218","article-title":"A normal reference of bone mineral density (BMD) measured by dual energy X-ray absorptiometry in healthy thai children and adolescents aged 5\u201318 years: a new reference for Southeast Asian Populations","volume":"9","author":"P Nakavachara","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"pone.0298914.ref025","doi-asserted-by":"crossref","first-page":"19434","DOI":"10.7448\/IAS.18.2.19434","article-title":"Tailored combination prevention packages and PrEP for young key populations","volume":"18","author":"A Pettifor","year":"2015","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"pone.0298914.ref026","doi-asserted-by":"crossref","first-page":"e25564","DOI":"10.1002\/jia2.25564","article-title":"CE-PID \u2010 TRC Adolescent Study Team. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial","volume":"5","author":"WN Songtaweesin","year":"2020","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"pone.0298914.ref027","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"L Van Damme","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0298914.ref028","doi-asserted-by":"crossref","first-page":"e1004097","DOI":"10.1371\/journal.pmed.1004097","article-title":"Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study","volume":"19","author":"JD Tapsoba","year":"2022","journal-title":"PLoS Med"},{"issue":"3","key":"pone.0298914.ref029","doi-asserted-by":"crossref","first-page":"e25896","DOI":"10.1002\/jia2.25896","article-title":"Low PrEP adherence despite high retention among transgender women in Brazil: the PrEParadas study","volume":"25","author":"PrEParadas Study Team","year":"2022","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"pone.0298914.ref030","doi-asserted-by":"crossref","first-page":"e25250","DOI":"10.1002\/jia2.25250","article-title":"Patterns and clinical consequences of discontinuing HIV preexposure prophylaxis during primary care","volume":"22","author":"D Krakower","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"pone.0298914.ref031","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10461-022-03782-7","article-title":"Risk Factors Associated with Loss to Follow-up Among Transgender Women Receiving HIV Pre-exposure Prophylaxis in Chiang Mai province, Thailand","volume":"27","author":"N Thongsak","year":"2023","journal-title":"AIDS Behav"},{"issue":"11","key":"pone.0298914.ref032","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/QAD.0000000000000647","article-title":"Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm","volume":"29","author":"JE Haberer","year":"2015","journal-title":"AIDS"},{"issue":"8","key":"pone.0298914.ref033","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1007\/s10461-022-03624-6","article-title":"Perceptions and Practicalities Influencing Pre-exposure Prophylaxis Adherence Among Men Who Have Sex with Men in England","volume":"26","author":"D Arnold-Forster","year":"2022","journal-title":"AIDS Behav"},{"issue":"10","key":"pone.0298914.ref034","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1177\/1359105319883927","article-title":"Impact of HIV risk perception on both pre-exposure prophylaxis and condom use","volume":"26","author":"M Di Ciaccio","year":"2021","journal-title":"J Health Psychol"},{"issue":"5","key":"pone.0298914.ref035","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/QAI.0000000000000362","article-title":"Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP","volume":"67","author":"FEM-PrEP Study Group","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"pone.0298914.ref036","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/09540121.2020.1810618","article-title":"Risk compensation in HIV PrEP adherence among Black men who have sex with men in HPTN 073 study","volume":"33","author":"DL Whitfield","year":"2021","journal-title":"AIDS Care"},{"issue":"3","key":"pone.0298914.ref037","doi-asserted-by":"crossref","first-page":"e25463","DOI":"10.1002\/jia2.25463","article-title":"The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study","volume":"23","author":"HPTN 082 study group","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"pone.0298914.ref038","article-title":"Multilevel Factors Impacting PrEP Engagement Among Young Gay Men and Young Transgender Women in Thailand: A Qualitative Analysis","author":"PA Newman","year":"2023","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"1","key":"pone.0298914.ref039","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jadohealth.2021.04.001","article-title":"Adherence to Pre-Exposure Prophylaxis in Adolescents and Young Adults: A Systematic Review and Meta-Analysis","volume":"70","author":"BA Allison","year":"2022","journal-title":"J Adolesc Health"},{"issue":"5","key":"pone.0298914.ref040","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cid\/ciy182","article-title":"Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis","volume":"67","author":"MW Traeger","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0298914.ref041","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2352-4642(20)30248-0","article-title":"Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial","volume":"4","author":"K Gill","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"pone.0298914.ref042","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/QAI.0000000000000857","article-title":"The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B","volume":"71","author":"iPrEx Study Team","year":"2016","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T13:30:22Z","timestamp":1708608622000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0298914"}},"subtitle":[],"editor":[{"given":"Peter A.","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0298914","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}